

ASX Announcement

7 September 2026

OncoSil Medical Secures \$5.6 million from Major Institutional Investors

Key highlights

- OncoSil Medical has received commitments for a total of \$5.6 million from its three largest institutional investors Pengana High Conviction Equities Fund, Regal Partners and Australian Ethical Investments
- Comprises a \$4.0 million placement and early exercise of OncoSil Medical listed options (\$1.6 million) at a 9.9% premium to last traded price
- Funds will support the commercial launch of the OncoSil™ device in the United States and Australia, following recent U.S. Food and Drug Administration (FDA) and Australian Therapeutic Goods Administration (TGA) approvals
- Strengthens pro-forma cash and cash equivalents to \$12.1 million¹
- The G-BA funded study, two additional European regulatory filings and Sydney manufacturing commencement is anticipated to be delivered in 1H FY27

Sydney, Australia – 7 September 2026: OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company developing targeted radiation therapies for difficult-to-treat cancers, is pleased to announce that it has received commitments for a total of \$5.6 million in new capital from a combination of a share placement and early exercise of listed options (ASX:OSLOE) from the Company’s three largest shareholders Pengana High Conviction Equities Fund, Regal Partners and Australian Ethical Investments.

A total of \$4.0 million by way of a placement at \$1.00, representing a 9.9% premium to the last closing price on 7 September 2026 and through the issue of 4.0 million shares in accordance with the Company’s existing placement capacity under ASX Listing Rule 7.1 and approximately \$1.6 million through the exercise of approximately 1.8 million OSLOE listed options at \$0.90. Allotment and issue of the placement shares and shares resulting from the exercise of the options is expected to occur on 10 September 2026, with normal trading expected to commence on 11 September 2026.

Dr Thomas Duthy, Chairman of OncoSil Medical, said:

“We thank our three largest institutional investors for their confidence in our business and outlook. With both FDA and TGA approvals secured this year, this capital will support our transition into commercialisation in the United States and Australia. The placement and early exercise of the listed options by our major holders, which are not due to expire until the end of June 2027, is a strong endorsement of our outlook in FY27 as we move rapidly towards multiple value accretive events for the Company with a strong balance sheet and a committed team.”

¹ Based on \$5.6 million raised and cash at 30 June 2026 of \$6.5 million

For personal use only



OncoSil Medical enhances path to commercialisation

OncoSil Medical has entered FY27 having achieved both of its principal regulatory objectives. Following approval by the Australian TGA in May 2026 for the treatment of locally advanced pancreatic cancer in addition to gemcitabine-based chemotherapy, and approval by the U.S. FDA in August 2026 under the Humanitarian Device Exemption pathway for unresectable, non-metastatic distal cholangiocarcinoma as an adjunct to systemic therapy. OncoSil™ is now approved for sale in more than 30 countries, including the United States and Australia.

OncoSil Medical is targeting several key 1H FY27 milestones, including the G-BA funded study, two additional European regulatory filings and commencement of manufacturing at the OncoSil Medical/Cyclotek facility, as shown below:

1H FY27

- OncoSil™ device US label filing to FDA (HDE)
- Presentation of TRIPP-FFX Clinical Trial Results at ESMO GI Congress
- Completion of validation of manufacturing at Cyclotek
- PALACROS European consortium | PULSE trial
- FDA HDE approval for distal cholangiocarcinoma (dCCA)
- Transitional Pass Through Payment Application: Centers for Medicare and Medicaid Services (CMS) - Reimbursement
- ISO 13485 Certification OncoSil | Cyclotek manufacturing facility
- G-BA funded study commencement
- EU regulatory submission – percutaneous label change (PANCOSIL)
- EU regulatory submission – FOLFIRINOX label change (TRIPP-FFX)
- Commercial sales from OncoSil | Cyclotek manufacturing facility in Sydney*

2H FY27

- EU regulatory approval – percutaneous label change (PANCOSIL)
- EU regulatory approval – FOLFIRINOX label change (TRIPP-FFX)
- Launch of OncoSil™ device in Australia
- Launch of OncoSil™ device in the United States

* Subject to approval

Click [here](#) to view this announcement on Investor Hub.

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 160 9642 4981	Mr. Tim Luscombe & Ms. Nova Taylor Joint Company Secretaries E: tim.luscombe@bio101.com & nova.taylor@bio101.com T: +61 429 707 079 & +61 414 877 703
--	--

About OncoSil Medical

OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical's mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (³²P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™, a single-use brachytherapy (internal radiation) device used to deliver a pre-determined dose of beta radiation directly into cancerous tissue. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

In the United States, OncoSil™ is indicated for the treatment of patients with distal cholangiocarcinoma (dCCA) that is both unresectable (locally advanced and/or unfit for surgery) and non-metastatic, as an adjunct to systemic therapy.

In markets outside the United States where OncoSil™ has received regulatory approval, OncoSil™ is indicated for the treatment of patients with unresectable locally advanced pancreatic cancer, in addition to gemcitabine-based chemotherapy.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year^[1]. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

Distal cholangiocarcinoma (dCCA) is a rare form of bile duct cancer. It is often diagnosed at an advanced stage, when surgical treatment may no longer be possible, and is associated with a poor prognosis.

OncoSil™ has received CE Marking approval, providing marketing authorisation in the European Union and the United Kingdom. OncoSil™ has also received approval from the U.S. Food and Drug Administration (FDA) under a Humanitarian Device Exemption (HDE) for the treatment of patients with unresectable, non-metastatic distal cholangiocarcinoma (dCCA), as an adjunct to systemic therapy. OncoSil™ has been designated as a Breakthrough Device in Europe and the United States. It is currently approved for sale in 30+ countries, including the European Union, United Kingdom, United States, Australia, Saudi Arabia, Türkiye and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel and the UK.

To learn more, please visit: www.oncosil.com/

^[1] <https://gco.iarc.fr/en>